title: Arachidonic acid mediates interferon-gamma-induced sphingomyelin hydrolysis and monocytic marker expression in HL-60 cell line.
abstract: The biochemical signaling mechanisms involved in transducing the effects of interferon-gamma (IFN-gamma) on human leukemia-derived HL-60 cell differentiation are not completely understood. Recent studies established the existence of a sphingomyelin (SM) cycle that operates in response to the action of IFN-gamma on HL-60 cells, but the mechanisms by which IFN-gamma induces the SM hydrolysis remain unexplored. In this study, biochemical events mediating IFN-gamma effects on SM turnover and their specificity and role in HL-60 differentiation were investigated. The activation of the SM cycle by IFN-gamma occurred rapidly, with a decrease of approximately 20% in the SM level observed after 60 minutes with a concomitant increase in ceramide level. Treatment of HL-60 cells with IFN-gamma did not influence the 1,2-diacylglycerol concentration, intracellular Ca2+ concentration, or phospholipase D activity. IFN-gamma stimulated a rapid release of arachidonic acid (AA) from HL-60 cells; the effect was abolished by the pretreatment of cells with pertussis toxin, suggesting a role for a pertussis-toxin-sensitive G protein in IFN-gamma-mediated activation of phospholipase A2 (PLA2). At 4 to 120 hours after the stimulation of the cells with IFN-gamma, a significant increase in the particulate and soluble PLA2 activity was observed, corresponding to an increase in the level of immunoreactive cPLA2 in both cytosol and membrane fractions. The treatment of cells with tyrosine kinase inhibitor herbimycin A completely abolished the effect of IFN-gamma on PLA2 activity in membrane and cytosolic fractions, but had no effect on IFN-gamma-mediated early AA release suggesting dual mechanism of PLA2 activation. Melittin, potent activator of PLA2, and AA mimicked the effect of IFN-gamma on SM hydrolysis. Pretreatment of HL-60 cells with the PLA2 inhibitor, bromophenacyl bromide (BPB), or pertussis toxin abolished the effect of IFN-gamma on SM hydrolysis; exogenous addition of AA overcame the effects of BPB and pertussis toxin. Long-term exposure (5 days) of HL-60 cells to IFN-gamma caused an increase in nitroblue tetrazolium (NBT)-reducing and nonspecific esterase (NSE) activity and induced expression of Fc gamma RI (CD64) without significant effects on cell number, adherence, or phagocytic activity. The treatment of cells with AA or melittin induced NBT, NSE, and CD64 expression to the level similar to that observed with IFN-gamma, and no further increase was observed with the combination of IFN-gamma and AA or IFN-gamma and melittin. Treatment of HL-60 cells with indomethacin, an inhibitor of cyclo-oxygenase, and nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenase, had no effects on IFN-gamma-mediated induction of CD64 expression. These studies indicate a key role for the phospholipase A2/AA pathway, as an early biochemical signal elicited by the occupation of IFN-gamma-receptor, in mediating IFN-gamma induction of the SM cycle and phenotypic changes associated with differentiation of HL-60 along monocytic lineage.
authors.affiliation: Department of Physiology, School of Medicine, University of Zagreb, Croatia.
authors.forename: D
authors.initials: D
authors.lastname: Visnjić
authors.forename: D
authors.initials: D
authors.lastname: Batinić
authors.forename: H
authors.initials: H
authors.lastname: Banfić
mesh_terms: D015703:Antigens, CD / Q000187:drug effects / Q000502:physiology; D016718:Arachidonic Acid / Q000502:physiology*; D016227:Benzoquinones; D002118:Calcium / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002518:Ceramides / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004075:Diglycerides / Q000378:metabolism; D004789:Enzyme Activation; D018922:HL-60 Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D007213:Indomethacin / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology*; D047029:Lactams, Macrocyclic; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009637:Masoprocol / Q000494:pharmacology; D008555:Melitten / Q000494:pharmacology; D008563:Membrane Lipids / Q000378:metabolism*; D009000:Monocytes; D037342:Pertussis Toxin; D010739:Phospholipase D / Q000378:metabolism; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D011809:Quinones / Q000494:pharmacology; D017452:Receptors, IgG / Q000096:biosynthesis; D017471:Receptors, Interferon / Q000187:drug effects / Q000502:physiology; D017828:Rifabutin / Q000031:analogs & derivatives; D015398:Signal Transduction / Q000502:physiology; D013109:Sphingomyelins / Q000378:metabolism*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology; D000096743:Interferon gamma Receptor
chemical_list: D015703:Antigens, CD; D016718:Arachidonic Acid; D016227:Benzoquinones; D002118:Calcium; D002518:Ceramides; D016861:Cyclooxygenase Inhibitors; D004075:Diglycerides; D007213:Indomethacin; D007371:Interferon-gamma; D047029:Lactams, Macrocyclic; D016859:Lipoxygenase Inhibitors; D009637:Masoprocol; D008555:Melitten; D008563:Membrane Lipids; D037342:Pertussis Toxin; D010739:Phospholipase D; D010741:Phospholipases A; D054467:Phospholipases A2; D011809:Quinones; D017452:Receptors, IgG; D017471:Receptors, Interferon; D017828:Rifabutin; D013109:Sphingomyelins; D010566:Virulence Factors, Bordetella; D000096743:Interferon gamma Receptor; C020754:herbimycin